Policy & Regulation
Sarclisa approved in EU for front-line treatment of transplant-ineligible multiple myeloma
22 January 2025 - French healthcare company Sanofi S.A. (Euronext Paris:SAN) (Nasdaq:SNY) said on Wednesday that the European Union has approved Sarclisa (isatuximab), in combination with bortezomib, ...
Novocure opens new global headquarters in Baar, Switzerland
22 January 2025 - Global oncology company Novocure (NASDAQ: NVCR) announced on Wednesday that it has officially inaugurated its new global headquarters in Baar, Canton of Zug, Switzerland. This move s...
Cytonics completes study of first nine patients in CYT-108 Phase 1 trial
22 January 2025 - Cytonics Corporation, a Florida-based private biotechnology company developing biologic therapies for musculoskeletal conditions, announced on Tuesday that the first nine patients in...
Life Molecular Imaging's [18F]florbetaben receives US FDA Fast Track Designation
22 January 2025 - German pharmaceutical company Life Molecular Imaging (LMI) announced on Tuesday that it has received Fast Track Designation from the US Food and Drug Administration (FDA) for its [18...
Stuart Therapeutics completes ST-100 (vezocolmitide) phase III study in Dry Eye Disease
22 January 2025 - Clinical-stage drug platform company Stuart Therapeutics Inc announced on Tuesday that it has completed the phase III study of its lead therapeutic candidate ST-100 (vezocolmitide) f...
Revelation Biosciences initiates Phase 1b clinical study of Gemini in CKD patients
21 January 2025 - Clinical-stage life sciences company Revelation Biosciences Inc (NASDAQ:REVB) on Tuesday announced the initiation of its PRIME Phase 1b clinical study of Gemini in patients with Stag...